Laden...
| No images? Click here Friday, 21 January 2022 MEDIA ADVISORY Virtual press conference on the outcomes of the Date and time: Friday, 21 January at 14.00 CET Subject: Outcomes of the extraordinary meeting of the WHO Strategic Advisory Group of Experts (SAGE) on Immunization held on 19 January 2022. Conclusions and recommendations are herein included; embargo lifts at 14.00 CET today, 21 January. Speakers: Prof Alejandro Cravioto, Chair, Strategic Advisory Group of Experts (SAGE) on ImmunizationDr Kate O’Brien, Director, Department of Immunization, Vaccines and Biologicals, WHODr Joachim Hombach, Executive Secretary SAGE, WHODr Annelies Wilder-Smith, Technical Advisor to the SAGE COVID-19 Working Group, WHOJoin the press conference: Zoom: Link: https://who-e.zoom.us/j/94571412949Password: VPCsageVPCPhone: Webinar ID: 945 7141 2949Numeric passcode for phone access: 1633695778International numbers available: https://who-e.zoom.us/u/aemgTtdxPu********************************** Outcomes and conclusions of the 19 January convening of the SAGE embargoed until 14.00 CET on 21 January Endorsed revisions to the WHO SAGE Roadmap for Prioritizing Uses of COVID-19 Vaccines, taking into account increasing vaccine availability, vaccine coverage rates, and the evolving epidemiological situation including variants of concern. Highlights: Draws from comprehensive evidence reviews conducted during Q4 of 2021;Considers scenarios in which vaccination coverage exceeds 50% of the population;Includes topics such as vaccine use in children and adolescents, as well as prioritization of additional and booster doses in relation to vaccination coverage rates;Expands further in lower priority use groups; andDevelops the concept of optimized vaccine use.Key conclusions: Countries with low rates of primary series coverage should first achieve high primary series coverage rates among the higher priority-use groups before offering vaccine doses to lower priority-use groups;Countries with moderate-to-high primary series coverage in higher priority-use groups should preferentially prioritize available vaccine supply to first achieve high booster dose coverage in higher priority-use groups before offering vaccine doses to lower priority-use groups.Updated Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine. Key revisions: Extends of the age indication down to the age of 5 years with a vaccine of reduced dosage (10 µg instead of 30 µg); andRecommends booster dose vaccination starting with the highest priority-use groups (e.g. older adults and health workers), 4 to 6 months after the completion of the primary series. These documents are expected to be available online at 14.00 CET today, 21 January. ********************************** What is SAGE? Further information: https://www.whoint/immunization/policy/sage/en/ ********************************** NOTE TO JOURNALISTS Please ensure you enter your name and media outlet (use name/outlet). Kindly note, only questions from media (one per journalist) are allowed. When you sign in you will be automatically put in the meeting room. WHO reserves the right to remove any participant whose behaviour causes any disruption. The event is also broadcast on WHO social media channels and you can follow it there. To ask a question, please click "raise hand" and this will enter you into the queue for questions. (It can be found under the tab: participants.) Please make sure you have a microphone connected or active on your computer. Do not ask questions via the chat as we cannot guarantee that we can incorporate them into the Q&A session. Due to the volume of questions, we are no longer able to take them from phone callers and interpretation is not available via telephone. Media contacts: You are receiving this NO-REPLY email because you are included on a WHO mail list.
|
Laden...
Laden...
© 2024
